• Why Attend?
  • Agenda
  • Advisory Board
  • Speakers
  • Plan Your Visit
  • Event Gallery
  • 2026 Sponsors
  • Media Centre
  • Presentations
  • Why partner?
  • Contact Us

Why Attend?

Agenda

  • 2 Dec 2026
  • 3 Dec 2026
Expand All

Streams

Stream one

STREAM A: Outsourcing & Clinical Operations

Stream two

STREAM B: Clinical Trial Supply

11:30 AM

Quality by Design in Clinical Supply: Driving Efficiency, Compliance, and Patient Safety

  • Embedding QbD principles across the clinical supply lifecycle to proactively manage risks
  • Strengthening risk-based quality management for compliance and supply continuity
  • Preparing quality-driven supply strategies for advanced therapies and complex trials

Speakers

Alicia Kim
Clinical Trials Team Leader, LN Robotics

12 PM

Reserved for Akesa

12:30 PM

KEYNOTE: Domestic vs Global CRO Competition: What It Means for Korean Clinical Supply

  • How the growth of domestic Korean CROs is reshaping vendor selection
  • Supply chain capability comparisons between local and global CRO, CMO, CDMO offerings
  • Where domestic CROs are closing the gap on international standards

Speakers

Seongyun Bang
Chief Development Officer, Vice President, SPARK Biopharma

1 PM

Lunch and networking

2:15 PM

PANEL DISCUSSION: Strengthening Collaboration Between Clinical Trial Supply and Clinical Operations

  • Ascertaining how clinical supply can get a seat at the table with clinical operations to streamline capabilities
  • Discovering how teams can collaborate and how technology can enable this
  • Sourcing raw materials in order to produce products
  • Overcoming logistical challenges within supply chain

Speakers

Seongyun Bang
Chief Development Officer, Vice President, SPARK Biopharma
Tina Karunaratne
Founder and President, Bridge to Compassionate Care
Tanuj Sircar
Associate Director, Competitive Intelligence, GlobalData

2:45 PM

Reserved for Phoenix Pharma

3:15 PM

From GDP Compliance to Global Standardisation: Building More Resilient Clinical Trial Cold Chains

  • Overview of ISO/TC315 and its relevance to pharmaceutical and clinical trial supply chains
  • Bridging the gap between current GMP/GDP expectations and future global standards
  • How standardised cold chain frameworks can reduce operational variability

Speakers

Kyoung Chul Hong
CEO, MegSpace

3:45 PM

Afternoon refreshments and networking

4:15 PM

The 2026 Clinical Trial Surge: Can Clinical Supply Keep Pace?

  • Exploring the key factors driving increased clinical trial activity in 2026
  • Discover the evolving clinical trial landscape and the opportunities it presents for suppliers and service providers this year
  • See how this has shaken up the biopharma competitive landscape and how this will affect the clinical trial supply chain

Speakers

Tanuj Sircar
Associate Director, Competitive Intelligence, GlobalData

4:45 PM

Implementing an effective IRT system in your clinical trial supply chain to streamline supply planning and management

  • Overcoming challenges around implementation and use of a new IRT system
  • How to leverage your IRT systems effectively to get the most out of your technology
  • Selecting an IRT vendor that meets your needs: essential factors and considerations in supplier selection

Speakers

Tina Karunaratne
Founder and President, Bridge to Compassionate Care

5:15 PM

Chairperson’s closing remarks

8 AM

Registration and refreshments

8:40 AM

Chairperson’s opening remarks

8:45 AM

KEYNOTE: The India Advantage: Rethinking Korea’s Clinical Trial Outsourcing Strategy

  • Asia-Pacific emerging as the fastest-growing region for clinical trial outsourcing, with India positioned at the center of that shift
  • Cost-competitive infrastructure without compromising data quality or regulatory rigor
  • Rethinking the strategy: from transactional to strategic

Speakers

Akhilesh Sharma
President & Chief Medical Officer Alkem Laboratories

9:15 AM

Reserved for Novotech

9:45 AM

PANEL DISCUSSION: How AI Is Transforming Clinical Operations: What’s Next?

  • Realistic AI applications in protocol drafting, demand forecasting and inventory management
  • Keeping pace with fast-moving AI development while maintaining trial integrity
  • AI, data and the changing role of the CRO/vendor

Speakers

Hyojin Park
Business Development Manager, GlobalData Healthcare
Megumi Ebara
Associate Director, Kyowa Kirin
Akhilesh Sharma
President & Chief Medical Officer Alkem Laboratories

10:15 AM

Reserved for Partners

10:45 AM

Morning refreshments and networking

11:30 AM

Operationalizing Trials in Resource-Limited Settings: Lessons from Vaccine Development

  • Key operational lessons learned from conducting large-scale vaccine trials in (LMICs)
  • Balancing rapid trial execution with regulatory compliance and Good Clinical Practice
  • Strategies for successful patient recruitment, retention, and community engagement in resource-limited settings
  • Ensuring data quality, oversight, and risk management across geographically dispersed trial sites

Speakers

Sunee Chuasuwan
Head of Clinical Operations and Trial Management, International Vaccine Institute (IVI)

12 PM

Reserved for Nucleus Network

12:30 PM

Optimising Early-Phase Clinical Development: Turning Challenges into Opportunities

  • Addressing common operational and scientific challenges in Phase 1 and Phase 2 trials
  • Managing complex protocol designs incorporating biomarkers and adaptive trial elements
  • Evaluating the necessity of placebo groups in Phase 1 studies

Speakers

Eun-Jihn Roh
NEX-I/Selecxine, Chief Development Officer

1 PM

Lunch and networking

2:15 PM

Patient Centricity: What Does Patient-Focused Clinical Trial Development Actually Look Like in 2026?

  • Checking out what's working and what could be better
  • Looking at the difference between research done purely for research versus for commercialization, and what that means for patients given today's

Speakers

Sooyoung Kim
Manager – Clinical Research Lead, Clinical Research Investigator Engagement, Delivery & Capabilities, lilly

2:45 PM

Reserved for MyData-TRUST

3:15 PM

CASE STUDY: AriBio’s AR1001: Korea’s First Global Blockbuster Candidate for Alzheimer’s

  • AR1001 is a first-in-class, oral, disease-modifying therapy poised to reshape Alzheimer's treatment after two decades of limited progress
  • We'll cover the scientific breakthroughs and strategic lessons behind its development
  • We'll highlight AriBio's focus on delivering the right therapy to the right patients, while meeting FDA and EMA regulatory standards

Speakers

Jae-Young Ha
Chief Business Officer, Aribio

3:45 PM

Afternoon refreshments and networking

4:15 PM

Selecting and Managing the Right CRO: A Strategic Guide for Korean Biotech

  • Determining when and how to engage a CRO across the clinical development lifecycle
  • Selecting a fit-for-purpose CRO based on program needs, risks and sponsor capabilities
  • Small/mid-sized CRO versus large global CRO: choosing the right operating model
  • Establishing effective governance and risk-proportionate sponsor oversight

Speakers

Hyerim Kang
Head of Clinical Development Unit, GC Biopharm

4:45 PM

KEYNOTE: US FDA Entry Strategy in 2026: How Korean Biotech Should Approach the US Market

  • Global market trends and US FDA regulatory perception
  • Establishing a strategy for New drug development in line with updated guidance from US FDA
  • FDA engagement strategy: pre-IND/IND and accelerated clinical programs

Speakers

Young Su (Bobby) Noh
Director, Head of Clinical Research and Development (ONCO),Hanmi Pharm

5:15 PM

Chairperson’s closing remarks

Streams

Stream one

STREAM A: Outsourcing & Clinical Operations

Stream two

STREAM B: Clinical Trial Supply

9 AM

From Manufacturing to Patient: Strengthening the Pharmaceutical Supply Chain Through Efficiency and Quality

  • Unpacking the challenges and complexities inherent in the full pharmaceutical supply chain journey, from production to final patient delivery
  • Navigating regulatory demands and ensuring ongoing compliance across the chain
  • Reviewing the practical strategies used to enhance performance and quality across the entire supply chain

Speakers

Jungwon Jung
Production Team Manager, HK inno-N

9:30 AM

Reserved for Partners

10 AM

Ensuring Supply Continuity for Short Half Life Radiopharmaceuticals in Global Clinical

  • Building redundancy into supply chains to mitigate risk from production, transport, or equipment failures
  • Managing complex customs, import/export, and radioactive materials regulations across trial countries
  • Ensuring quality control and radiopharmaceutical stability testing within extremely narrow time windows

Speakers

Katrien Aerts
Advisor, Affibody

10:30 AM

Reserved for Partners

11 AM

Morning refreshments and networking

11:45 AM

Strengthening Cold Chain Resilience: Addressing Emerging Challenges in Temperature-Controlled Clinical Supply

  • Overcoming the latest challenges in global cold chain logistics for clinical trials
  • Identifying common risks and mitigation strategies for international temperature-controlled shipments
  • Leveraging real-time temperature monitoring and digital technologies to enhance shipment visibility

Speakers

KangPyo Lee
Vice President, Hanul TL

12:15 PM

PANEL DISCUSSION: AI’s Reach in Clinical Supply: How Far Are We From the Ceiling?

  • Exploring realistic AI applications across forecasting, inventory management and distribution planning for Korean and regional trials
  • Keeping pace with fast-moving AI development while maintaining trial integrity and regulatory alignment
  • AI, data and the changing role of the CRO/vendor in Korea's clinical supply ecosystem

Speakers

Katrien Aerts
Advisor, Affibody
Tanuj Sircar
Associate Director, Competitive Intelligence, GlobalData
KangPyo Lee
Vice President, Hanul TL

1 PM

Lunch and networking

Prize Draw taking place in exhibition hall at 14:15

Join us for a chance to win one of our prizes, including Apple products

2:30 PM

Speaker Hosted Afternoon Tea & Chat

Connect, chat, and exchange ideas over an informal afternoon tea experience with industry leaders and peers.

This interactive session offers a unique opportunity to step away from the main stage, join conversations that matter, and gain practical insights from professionals tackling similar challenges across the clinical trials and clinical supply ecosystem.

Share your experiences, ask questions, and build new relationships in a relaxed and engaging environment.

Roundtable session lasts for 30 minutes and rotate

TOPIC 1: Risk Management Strategies: How Small Biotech’s Can Plan Ahead and Minimise Challenges

Hyojin Park, Business Development Manager, GlobalData Healthcare

TOPIC 2: Driving Efficiency and Results Through Strong Sponsor, CRO Partnerships

Tina Karunaratne, Founder and President, Bridge to Compassionate Care

TOPIC 3: Connecting Packaging and Labelling with End-to-End Clinical Supply Chain Strategies

Speakers

Hyojin Park
Business Development Manager, GlobalData Healthcare
Tina Karunaratne
Founder and President, Bridge to Compassionate Care

3:30 PM

END OF CONFERENCE

8:15 AM

Registration and refreshments

8:50 AM

Chairperson’s opening remarks

9 AM

Optimizing CRO Partnerships for Successful Clinical Trial Delivery

  • Identifying the right point for CRO involvement to improve efficiency and execution
  • Leveraging CRO insights to optimize protocol design, country selection, and study feasibility
  • Establishing clear communication, shared accountability, and collaborative ways of working

Speakers

Jaesun Kang
Director/Clinical operation office, Cha bio

9:30 AM

Reserved for Emmes Group

10 AM

CASE STUDY: Advancing Clinical Development Through Meaningful Patient Engagement

  • Embedding patient voices into research, development, and lifecycle management
  • Building a structured framework to gather, evaluate, and apply patient insights
  • Enhancing clinical outcomes through patient-driven innovation
  • Success story: Transforming the patient journey with an on-body injector for chemotherapy care

Speakers

Megumi Ebara
Associate Director, Kyowa Kirin

10:30 AM

Reserved for QPS

11 AM

Morning refreshments and networking

11:45 AM

From In-Licence to First Patient: Trial Design Lessons for an Acquired Asset

  • Assessing the existing clinical evidence and data gaps when taking on a licensed-in asset
  • Translating the asset’s development strategy into an optimized clinical trial design
  • Aligning internal teams, external partners, and investigators to accelerate study start-up and first-patient-in

Speakers

Alex Shin
Director, Clinical Development, Sovargen

12:15 PM

PANEL DISCUSSION: From Good to Great: High-Performing Sponsor-CRO Partnerships in 2026

  • Moving beyond transactional oversight toward a genuine strategic partnership model
  • Aligning financial incentives so both sponsor and CRO win when a trial performs well
  • Leveraging joint innovation initiatives (AI, digital tools, process redesign) as a partnership accelerant rather than a point of friction
  • Defining what "great" actually looks like from both the sponsor's and the CRO's perspective before trying to get there

Speakers

Hyojin Park
Business Development Manager, GlobalData Healthcare
Megumi Ebara
Associate Director, Kyowa Kirin
Alex Shin
Director, Clinical Development, Sovargen

1 PM

Lunch and networking

Prize Draw taking place in exhibition hall at 14:15

Join us for a chance to win one of our prizes, including Apple products

2:30 PM

Speaker Hosted Afternoon Tea & Chat

Connect, chat, and exchange ideas over an informal afternoon tea experience with industry leaders and peers.

This interactive session offers a unique opportunity to step away from the main stage, join conversations that matter, and gain practical insights from professionals tackling similar challenges across the clinical trials and clinical supply ecosystem.

Share your experiences, ask questions, and build new relationships in a relaxed and engaging environment.

Roundtable session lasts for 30 minutes and rotate

TOPIC 1: Risk Management Strategies: How Small Biotech’s Can Plan Ahead and Minimise Challenges

Hyojin Park, Business Development Manager, GlobalData Healthcare

TOPIC 2: Driving Efficiency and Results Through Strong Sponsor, CRO Partnerships

Tina Karunaratne, Founder and President, Bridge to Compassionate Care

TOPIC 3: Connecting Packaging and Labelling with End-to-End Clinical Supply Chain Strategies

Speakers

Hyojin Park
Business Development Manager, GlobalData Healthcare
Tina Karunaratne
Founder and President, Bridge to Compassionate Care

3:30 PM

END OF CONFERENCE

Speakers

Select a speaker to learn more

Back
Hyojin Park
Business Development Manager, GlobalData Healthcare

Hyojin Park, Ph.D., is a thought leader in Korea at GlobalData, where he leads consulting and data solution work for pharmaceutical, biotech, and government clients. He previously spent four years at Clarivate on due diligence, repositioning, and competitive intelligence projects, and was an author of the Drugs to Watch series. He holds a Ph.D. in Medical Science from Yonsei University College of Medicine and has been a regular speaker on global R&D and investment trends for over 8 years.

Session Details:

Speaker Hosted Afternoon Tea & Chat

2026-12-03, 2:30 PM

Session Details:

Speaker Hosted Afternoon Tea & Chat

2026-12-03, 2:30 PM

Session Details:

PANEL DISCUSSION: How AI Is Transforming Clinical Operations: What’s Next?

2026-12-02, 9:45 AM

Session Details:

PANEL DISCUSSION: From Good to Great: High-Performing Sponsor-CRO Partnerships in 2026

2026-12-03, 12:15 PM

View In Agenda
Next speaker
Back
Akhilesh Sharma
President & Chief Medical Officer Alkem Laboratories

Dr Akhilesh Sharma is an M.D. from Mumbai and Fellow of Royal Liverpool hospital society-U.K, with advanced training in Clinical Research from Berkley Extension, California State University, USA and PV from Luton Medical Centre, UK.

A visionary pharmaceutical executive with 30+ years’ experience in development of NCEs, biologics, cell & gene therapies, and complex generics. His expertise spans AI – driven drug development, translational medicine, biomarker development, Clinical R&D, market access, regulatory strategy, executive leadership, BD & global partnership across multinational pharmaceutical companies, based out of US & India.

He has a proven track record in building and leading high-performance global functions at Alkem, Dr. Reddy’s, Glenmark, Rhône-Poulenc Rorer (Aventis), Carter Wallace, Cell Therapeutics Inc. and as an entrepreneur with GeneXY (biomarker development organization in Philadelphia, jointly with Wistar institute, Pennsylvania University campus), RYTUS Therapeutics.

He combines scientific depth with commercial acuity to forge academic co-development partnerships with Harvard, Johns Hopkins, U. Chicago, Texas Tech University-Medical Sciences, Memorial Sloan Kettering, Miami University, NIH, Karolinska, IIT-Bombay/ Kanpur, IISc-Bangalore; and others, at the same time unlocks successful regulatory pathways with agencies worldwide such as US FDA, EMA, MHRA, TGA, MCC, DCGI, and translate innovation into measurable business value. He has created more than $6500M+ innovation driven patented product portfolio during his entire tenure.

He is the Founding Director of Alixer NexGen Therapeutics Ltd., Alkem’s independent wholly owned Proprietary Subsidiary; and currently serves as President & Chief Medical Officer of Alkem Laboratories Ltd. He also serves on Board of Directors of Haystacks Analytics Pvt Ltd

In addition, he is an advisor to special projects at Harvard-Wyss, visiting faculty at Johns Hopkins University, Harvard-Wyss, (USA), Karolinska, Europe, IIT’s (premium technology institutes-India) and others. Been on panel of Drug Development, Clinical Research and Drug Safety at various national and international forums including at USFDA workshops and an invited faculty at leading international conferences & institutes.

He has to his credit more than 71 scientific & research publications, 58 patents and holds membership of International Pharmaceutical Society, American Academy of Dermatology, American Diabetes Association, European Society of Respiratory Medicine. He has been honored with a Lifetime Achievement Award in recognition of his contributions to biotechnology innovation and the development of cutting-edge therapies for patients.

Session Details:

KEYNOTE: The India Advantage: Rethinking Korea’s Clinical Trial Outsourcing Strategy

2026-12-02, 8:45 AM

Session Details:

PANEL DISCUSSION: How AI Is Transforming Clinical Operations: What’s Next?

2026-12-02, 9:45 AM

View In Agenda
Next speaker
Back
Kyoung Chul Hong
CEO, MegSpace

Session Details:

From GDP Compliance to Global Standardisation: Building More Resilient Clinical Trial Cold Chains

2026-12-02, 3:15 PM

View In Agenda
Next speaker
Back
Katrien Aerts
Advisor, Affibody

Session Details:

Ensuring Supply Continuity for Short Half Life Radiopharmaceuticals in Global Clinical

2026-12-03, 10:00 AM

Session Details:

PANEL DISCUSSION: AI’s Reach in Clinical Supply: How Far Are We From the Ceiling?

2026-12-03, 12:15 PM

View In Agenda
Next speaker
Back
Sunee Chuasuwan
Head of Clinical Operations and Trial Management, International Vaccine Institute (IVI)

Session Details:

Operationalizing Trials in Resource-Limited Settings: Lessons from Vaccine Development

2026-12-02, 11:30 AM

View In Agenda
Next speaker
Back
Jae-Young Ha
Chief Business Officer, Aribio

Session Details:

CASE STUDY: AriBio’s AR1001: Korea’s First Global Blockbuster Candidate for Alzheimer’s

2026-12-02, 3:15 PM

View In Agenda
Next speaker
Back
Seongyun Bang
Chief Development Officer, Vice President, SPARK Biopharma

Seong-Youn Bang is a senior professional with more than 26 years of experience across pharmaceutical companies, biotechnology firms, domestic and international CROs, and academia. Her expertise spans new drug clinical development, global project management, and related regulatory and quality functions. She currently serves as President of TRIALIGN Consulting and as a Senior Consultant at YNB Partners, advising on clinical development and operational strategy for new drugs, as well as global regulatory and quality matters.

Her key leadership roles have included Chief Operating Officer (COO) at Spark Biopharma, Head of Cell and Gene Therapy Development at GC Cell, and COO and Head of Drug Development at major biotechnology companies. She has also served as Country Head of PAREXEL International Korea and as Executive Vice President overseeing the Clinical Business Division at DreamCIS. In these positions, she played a central executive role in new drug and clinical development and clinical trial operations. From 2014 to 2020, she further strengthened her clinical trial expertise in healthcare and academia as Deputy Director of the Clinical Trial Center at CHA Bundang Medical Center and Associate Professor at CHA University.

Session Details:

PANEL DISCUSSION: Strengthening Collaboration Between Clinical Trial Supply and Clinical Operations

2026-12-02, 2:15 PM

Session Details:

KEYNOTE: Domestic vs Global CRO Competition: What It Means for Korean Clinical Supply

2026-12-02, 12:30 PM

View In Agenda
Next speaker
Back
Hye-Yeon Jeon
Head of Clinical Operations, Korean Cancer Study Group (KCSG)
Next speaker
Back
KangPyo Lee
Vice President, Hanul TL

Session Details:

Strengthening Cold Chain Resilience: Addressing Emerging Challenges in Temperature-Controlled Clinical Supply

2026-12-03, 11:45 AM

Session Details:

PANEL DISCUSSION: AI’s Reach in Clinical Supply: How Far Are We From the Ceiling?

2026-12-03, 12:15 PM

View In Agenda
Next speaker
Back
Eun-Jihn Roh
NEX-I/Selecxine, Chief Development Officer

Eun-Jihn Roh, R.Ph, MS, is a clinical development executive with more than 20 years of experience across global pharmaceutical companies, CROs, and biotechnology companies, including over 15 years in oncology drug development. She currently serves as Chief Development Officer at Nex-I and Selecxine, where she leads global clinical and regulatory strategy for early-stage oncology programs. Her experience spans first-in-human through pivotal studies, FDA and MFDS interactions, clinical trial design, CRO oversight, business development, and global study execution.

Session Details:

Optimising Early-Phase Clinical Development: Turning Challenges into Opportunities

2026-12-02, 12:30 PM

View In Agenda
Next speaker
Back
Alex Shin
Director, Clinical Development, Sovargen

Session Details:

From In-Licence to First Patient: Trial Design Lessons for an Acquired Asset

2026-12-03, 11:45 AM

Session Details:

PANEL DISCUSSION: From Good to Great: High-Performing Sponsor-CRO Partnerships in 2026

2026-12-03, 12:15 PM

View In Agenda
Next speaker
Back
Alicia Kim
Clinical Trials Team Leader, LN Robotics

- 23Y Clinical Trial & New Drug Development Expert Professional

- Global & Local Trials Experiences including the 1st Phase 2 COVID-19 New Oral-drug Trial PM in Korea & USA

- Global CROs and Local Pharmacies Experiences

- All-round Experts in Clinical Trials (Medicines & Devices)

Session Details:

Quality by Design in Clinical Supply: Driving Efficiency, Compliance, and Patient Safety

2026-12-02, 11:30 AM

View In Agenda
Next speaker
Back
Megumi Ebara
Associate Director, Kyowa Kirin

Session Details:

CASE STUDY: Advancing Clinical Development Through Meaningful Patient Engagement

2026-12-03, 10:00 AM

Session Details:

PANEL DISCUSSION: How AI Is Transforming Clinical Operations: What’s Next?

2026-12-02, 9:45 AM

Session Details:

PANEL DISCUSSION: From Good to Great: High-Performing Sponsor-CRO Partnerships in 2026

2026-12-03, 12:15 PM

View In Agenda
Next speaker
Back
Sooyoung Kim
Manager – Clinical Research Lead, Clinical Research Investigator Engagement, Delivery & Capabilities, lilly

2014 건국대학교 수의학과 졸업/ DVM License

2017-2020 Celltrion Clinical Operation/ Budget & Contract management

2020-2025 SK Bioscience Clinical Operation/CRA, CPM, Clinical Strategy/Medical Writer

2025 - Current Eli Lilly Investigator Engagement - Clinical Research Lead

Sooyoung Kim is a Clinical Research Lead at Eli Lilly, responsible for leading the initiation and operational execution of clinical trials for Lilly molecules. His work focuses on country feasibility, site selection, patient enrollment, and investigator engagement. He has over 10 years of experience in the pharmaceutical industry and brings deep expertise in clinical operations, spanning roles at Celltrion, SK Bioscience and Eli Lilly. He holds a Doctor of Veterinary Medicine degree and is a licensed veterinarian.

Session Details:

Patient Centricity: What Does Patient-Focused Clinical Trial Development Actually Look Like in 2026?

2026-12-02, 2:15 PM

View In Agenda
Next speaker
Back
Hyerim Kang
Head of Clinical Development Unit, GC Biopharm

Career history

Current: Head of Clinical Development Unit

  • Biotechs: clinical project director
  • Samsung Bioepis: clinical program lead
  • UCB: head of Clinical Project Management/ Site & patientsolution Asia lead
  • Roche: vendor manager

IQVIA: CRA & regional start-up lead

Session Details:

Selecting and Managing the Right CRO: A Strategic Guide for Korean Biotech

2026-12-02, 4:15 PM

View In Agenda
Next speaker
Back
Young Su (Bobby) Noh
Director, Head of Clinical Research and Development (ONCO),Hanmi Pharm

Young Su (Bobby) Noh, Ph.D., is the Director, Head of Global Regulatory Affairs, Hanmi Pharma and a representative of IFPMA, ICH E22 informal Expert Working Group.

Dr. Noh is also working as a committee member of KIC2026 and training on ICH guideline2026, an external Instructor in KoNECT and a reviewer of external evaluation committee of KDDF.

Previously, Dr. Noh successfully served as the Head of Clinical Research and Development (Biometrics, Clinical Science, and Clinical Operation), leading clinical programs with NMEs or NBEs in multi-therapeutic area: including metabolic diseases and rare diseases as well as oncology and hematology for 17 years.

Dr. Noh also served as an adjunct professor, department of regulatory science for Kyung Hee university and an expert, several guidelines Working Group of MFDS.

Dr. Noh received his Ph.D. in pharmacy Kyung Hee University.

Session Details:

KEYNOTE: US FDA Entry Strategy in 2026: How Korean Biotech Should Approach the US Market

2026-12-02, 4:45 PM

View In Agenda
Next speaker
Back
Jungwon Jung
Production Team Manager, HK inno-N

-1997 ~ 1999        :  KATRI (Korea apparel test and research institute)
- 2000 ~ 2001        :  Green Cross     

- 2001 ~ Present   :  HK inno-N. (old CJ Healthcare)

* 2001 ~ 2010 Quality Assurance Team

* 2010 ~ 2015 Technical development Team

* 2015 ~ 2017 Quality Manager

* 2017 ~ 2019 Project TF team (Head office) for New Plan & Bio Project

* 2019 ~ 2022 Quality Unit Manager (Cell and Gene Therapy Plant

* 2022 ~          Manufacturing2 Team Manager (LVP)

Session Details:

From Manufacturing to Patient: Strengthening the Pharmaceutical Supply Chain Through Efficiency and Quality

2026-12-03, 9:00 AM

View In Agenda
Next speaker
Back
Jaesun Kang
Director/Clinical operation office, Cha bio

Session Details:

Optimizing CRO Partnerships for Successful Clinical Trial Delivery

2026-12-03, 9:00 AM

View In Agenda
Next speaker
Back
Tina Karunaratne
Founder and President, Bridge to Compassionate Care

Session Details:

PANEL DISCUSSION: Strengthening Collaboration Between Clinical Trial Supply and Clinical Operations

2026-12-02, 2:15 PM

Session Details:

Implementing an effective IRT system in your clinical trial supply chain to streamline supply planning and management

2026-12-02, 4:45 PM

Session Details:

Speaker Hosted Afternoon Tea & Chat

2026-12-03, 2:30 PM

Session Details:

Speaker Hosted Afternoon Tea & Chat

2026-12-03, 2:30 PM

View In Agenda
Next speaker
Back
Tanuj Sircar
Associate Director, Competitive Intelligence, GlobalData

Session Details:

PANEL DISCUSSION: Strengthening Collaboration Between Clinical Trial Supply and Clinical Operations

2026-12-02, 2:15 PM

Session Details:

The 2026 Clinical Trial Surge: Can Clinical Supply Keep Pace?

2026-12-02, 4:15 PM

Session Details:

PANEL DISCUSSION: AI’s Reach in Clinical Supply: How Far Are We From the Ceiling?

2026-12-03, 12:15 PM

View In Agenda
Next speaker

Advisory Board

Select a member to learn more

Back
Chris Wallace
Head of Distribution EMEA, Argenx

Chris has over 35 years’ varied supply chain experience, having worked for several blue chip companies in a number of industries including 3rd party logistics services, automotive, medical device, nuclear fuels and biotech/pharmaceuticals.

Originally from the UK but now based in Switzerland, he has been involved in life science - biotech/pharmaceuticals & medical device - for over 20 years of his career and has latterly been SVP Global Supply Chain at Clover Biopharmaceutical before last year moving to Argenx as Head of Distribution EMEA.

He has developed, implemented and managed global healthcare supply chain strategies and operations on 6 continents. This has included different set-ups in multiple countries, including many in the Emerging Markets as well as the developed world.

Chris has a degree in economics from Manchester University, an MBA from Aston University and a postgraduate diploma from London University. In his spare time, he plays golf badly and loves to sample great Italian food and red wines!

Next
Back
Luiz Barberini
Head of External Manufacturing, Latin America, Bayer
  • Over 25 years’ experience in Logistics, Supply Chain, Procurement and Demand Planning areas.
    Solid knowledge and experience in the whole S&OP process and its KPI´s inter-relationships with stakeholders
  • Demand Planning process management - pre-S&OP, with Sales, Marketing, Trade Marketing, Industrial Planning and Finance and customized tool design for such process
  • Management skills: experience with multidisciplinary and international teams (Brazil / Latin America / US).
  • Experience in S&OP, 3PL and Supply Chain Organization projects' implementation
  • Strong experience with Pharmaceutical and Consumer companies and Brazilian distribution model / 3PL contracts
  • Solid team management skills, as well as Customer Service relationship and management
  • Teacher for major Post Graduation Schools - Demand Planning and Procurement/Negotiation areas

CSCP & CPIM APICS. Logistics & Supply Chain driven strategy. Distribution & Logistics, Demand Planning, S&OP, Procurement and Export experiences, focusing on Business necessities through effective leadership.

Working as External Manufacturing Operations Manager Latin America at Bayer, in charge for external partners for CHC Division. Previously as Relationship Associated Director at Merck , Logistics Manager at Takeda/Nycomed Pharma, focusing on demand management, planning and distribution activities. Also has worked as Pfizer´s Logistic Manager and EFD´s Supply Chain Manager. Souza Cruz´s Procurement Manager and Rhodia's Logistic Supervisor.

Specialties: Logistics, Supply Chain, Materials, Procurement , Services, Negotiation, 3PL contracts, S&OP, Demand Planning

Next
Back
Amanda Briceno
Clinical Supply Management & Patient Centricity Unit Manager, Chiesi Farmaceutici

Amanda Briceno is an experienced clinical supply professional with over 10 years in clinical research and supply chain operations. Originally from Venezuela, now based in Italy. She currently serves as Clinical Supply Manager and Head of the Patient Centricity Unit at Chiesi Farmaceutici, where she leads initiatives to design and deliver patient-focused clinical supply solutions that improve trial compliance and enhance the experience of both patients and site staff.

Her career began as a Clinical Research Associate at IQVIA, where she gained extensive experience in global trial monitoring and operations. Since joining Chiesi, Amanda has held positions of increasing responsibility within the Clinical Supply department, before assuming her current leadership role.

Amanda holds a Master’s degree in Drug Biotechnology from the Università degli Studi di Milano and a Bachelor’s degree in Medical Biotechnology. Amanda brings a strong blend of technical knowledge and operational leadership. Passionate about innovation in clinical supplies, she is dedicated to advancing more accessible, patient-centric clinical trials.

Next
Back
Paul Hingst
Supply Chain Consultant, Crinetics Pharmaceuticals

Paul is an experienced Clinical Supply Chain Professional with a 25-year career in the BioPharmaceutical industry.  His extensive career includes roles at major companies like Amgen and Thermo Fisher Scientific, where he honed his skills and made a significant impact.  He has served in varied roles from basic research and contract manufacturing to client services and account management.  He is a Principal Consultant and Co-Founder of Beacon BioPharm Associates, a clinical supply chain consulting firm, providing variable staffing solutions to small and mid-sized BioPharm clients.  Paul is an industry veteran and respected leader known for his expertise in clinical supply chain.

Next
Back
Amaury Jeandrain
Strategy Advisor, Clinical Supply, N-SIDE

Amaury Jeandrain has a Master’s Degree in Business Engineering with a specialization in supply chain optimization. He joined Clinigen in 2015, then N-SIDE in 2016 where he last  held the position of VP of Strategy for clinical supply solutions.

Over the past decade, his objective has been to make clinical trial supply chains more efficient by redefining CTS strategies and driving measurable performance improvements. His expertise also includes forecasting, planning, waste reduction, and shortage risk mitigation.

Since 2024, while accompanying his wife on humanitarian missions abroad (Niger, then Colombia), Amaury has continued his work as a CTS advisor and trainer, partnering with pharmaceutical companies worldwide to enhance clinical supply performance.

Next
Back
Francesco Santo
Director Clinical Supply Chain,
Orano Med

A highly experienced and passionate Director Clinical Supply Chain, Francesco has dedicated the past 17 years to ensuring the seamless execution of clinical trials by optimizing supply chain operations. His deep commitment to this field is driven by a relentless pursuit of excellence in delivering life-saving treatments to patients worldwide.  Throughout his career, he has honed a diverse skill set, encompassing:

  • Strategic Supply Chain Management
  • Regulatory Compliance
  • Cross-Functional Collaboration
  • Risk Management
  • Innovative Problem-Solving

Francesco’s dedication to the clinical supplies industry is rooted in a profound understanding of the critical role it plays in advancing medical research and improving patient outcomes. He is committed to continuing his journey in this field, always striving to contribute to the betterment of global health.

Next
Back
Arnaud Dourlens
Global Head of Clinical Supply Chain Operations, Sanofi

Arnaud Dourlens is an Arts et Métiers engineer, he began his industrial career in the FMCG sector where he held growing responsibilities. Then he joined the LVMH group where he reorganized new product launches and industrial investments in the Make-up segment in order to adapt to the need for innovation and time to market, thus providing a competitive advantage. He then managed the entire portfolio of industrial launches and investments in Perfumes, Skincare and Make-up for Parfums Christian Dior Group.

During his career Arnaud held a wide variety of industrial roles. He joined Sanofi in 2017 as Production Director of a major solid oral form production site (>2.5 billion € turnover). He has been a key player in the development of the continuous improvement mindset and in the transformation of the site through IT projects, investments and activity growth following the acquisition of Boehringer Ingelheim consumer healthcare portfolio.

Since the beginning of 2020, he’s been the global head of Sanofi Clinical Supply Chain Operations, managing worldwide clinical supply teams involved in more than 300 clinical studies.

Next
Back
Paul Larochelle
Senior Director Global Clinical Supply Chain,
Takeda

Paul Larochelle currently serves as Senior Director (Planning Team Lead) for Global Clinical Supply Chain at Takeda, where he serves as a member of the GCSC Leadership Team and is responsible for managing a team of professionals overseeing the forecasting and planning of clinical study supplies. His role encompasses the strategic and operational aspects of clinical supply chain management in therapeutic areas such as oncology, neuroscience, gastrointestinal diseases, vaccines, and rare diseases. Paul's leadership extends to cross-functional projects aimed at implementing new capabilities, conducting due diligence of potential acquisitions by the company, and improving existing processes. 

Previously, Paul held various roles at Biogen Corporation and Genzyme, a Sanofi Company, where he honed his expertise in clinical asset planning and clinical supplies management. His contributions to these organizations included serving as a lead contact for multiple clinical programs, developing supply chain strategies, leading continuous improvement projects, and serving as Fellowship Coordinator and Student Preceptor for dozens of students. 

Paul has a BS in Biology from Providence College, PharmD from MCPHS Boston, and an MBA from Worcester Polytechnic Institute. He also completed a Post-PharmD Industry Fellowship in Clinical Research/Investigational Product Management with MCPHS-Worcester and Genzyme Corporation. He is Chair of the Dean's Advisory Board at MCPHS School of Pharmacy – Boston,  a member of the Pharmacy Advisory Board at Western New England University, and a member of the Advisory Board for the Clinical Trial Supply global conference series. 

Next

Plan Your Visit

JW Marriott Dongdaemun Square Seoul

279, Cheonggyecheon-ro, Jongno-gu Seoul, South Korea, 03198

Outsourcing in Clinical Trials & Clinical Trial Supply Korea discounted room rate - KRW360,000 (excl. tax, breakfast an additional KRW30,000)

Arena International Events Group “(Arena”) is aware of numerous third-party agencies which are contacting Arena’s customers and purporting to have access to hotel room bookings, events attendee lists and selling unsolicited services. It is unclear whether the agencies in question are in possession of such information, or whether they intend to scam unsuspecting customers. Whilst Arena International Events Group pursues such third-party companies for their potentially illicit activity, Arena encourages you to be cautious in engaging with such third-party agencies and Arena shall not accept any responsibility for any losses incurred by you should you choose to engage with third parties that have no affiliation to Arena International Events Group..

2026 Sponsors

Select a sponsor to learn more

Featured Sponsor

Session Sponsor

Technology Showcase Sponsor

Exhibitors

Why partner?

 

Contact us to become a partner

Partnership Opportunities

We work with you to design a bespoke package to meet your business needs, where you could:

  • Demonstrate your expertise on the agenda – have the attention of the entire audience. For greatest impact, why not position your talk before a networking break and immediately conduct follow up conversations with highly engaged attendees
  • Showcase your business and its services at an exhibition booth, which provides a perfect meeting place for prospective new clients
    Present the value proposition of your offering over your competitors, in front of an audience of active, engaged potential customers
  • Speak with key decision makers as part of our intimate, interactive roundtable style workshop sessions with over 8 hours allowed for networking

Event reach

  • 150+ attendees each year
  • 80% attendees C-suite level

 

Take a look at our current sponsors

Media Centre

Become A Media Partner

Presentations

Enquiry

Contact Us

SPONSORSHIP ENQUIRIES

Jarvinder Sidhu

Senior Sales Executive

+44 207947 2755

SPEAKER ENQUIRIES

Ranhee Yoo

Conference Producer

+44 207947 2793

MARKETING ENQUIRIES

Moona Popal

Senior Marketing Manager

DELEGATE ENQUIRIES

Sunny Saikia

VIP Delegate Manager

SPONSORSHIP ENQUIRIES


Senior Sales Executive

Jarvinder Sidhu


+44 207947 2755

SPEAKER ENQUIRIES


Conference Producer

Ranhee Yoo


+44 207947 2793

MARKETING ENQUIRIES


Senior Marketing Manager

Moona Popal


 

DELEGATE ENQUIRIES


VIP Delegate Manager

Sunny Saikia